Cargando…
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
In drug development, the “onus” of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or “binding” functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating man...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449898/ https://www.ncbi.nlm.nih.gov/pubmed/26075248 http://dx.doi.org/10.1155/2015/605427 |
_version_ | 1782373924647993344 |
---|---|
author | Zurdo, Jesús Arnell, Andreas Obrezanova, Olga Smith, Noel Gómez de la Cuesta, Ramón Gallagher, Thomas R. A. Michael, Rebecca Stallwood, Yvette Ekblad, Caroline Abrahmsén, Lars Höidén-Guthenberg, Ingmarie |
author_facet | Zurdo, Jesús Arnell, Andreas Obrezanova, Olga Smith, Noel Gómez de la Cuesta, Ramón Gallagher, Thomas R. A. Michael, Rebecca Stallwood, Yvette Ekblad, Caroline Abrahmsén, Lars Höidén-Guthenberg, Ingmarie |
author_sort | Zurdo, Jesús |
collection | PubMed |
description | In drug development, the “onus” of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or “binding” functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a “holistic” interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole. In this new context, early risk assessment, using developability methodologies and computational methods in particular, can assist in reducing risks during development in a cost-effective way. We define specific areas of risk and how they can impact product quality in a broad sense, including essential aspects such as product efficacy and patient safety. Emerging industry practices around developability are introduced, including some specific examples of applications to biotherapeutics. Furthermore, we suggest some potential workflows to illustrate how developability strategies can be introduced in practical terms during early drug development in order to mitigate risks, reduce drug attrition and ultimately increase the robustness of the biopharmaceutical supply chain. Finally, we also discuss how the implementation of such methodologies could accelerate the access of new therapeutic treatments to patients in the clinic. |
format | Online Article Text |
id | pubmed-4449898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44498982015-06-14 Early Implementation of QbD in Biopharmaceutical Development: A Practical Example Zurdo, Jesús Arnell, Andreas Obrezanova, Olga Smith, Noel Gómez de la Cuesta, Ramón Gallagher, Thomas R. A. Michael, Rebecca Stallwood, Yvette Ekblad, Caroline Abrahmsén, Lars Höidén-Guthenberg, Ingmarie Biomed Res Int Review Article In drug development, the “onus” of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or “binding” functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a “holistic” interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole. In this new context, early risk assessment, using developability methodologies and computational methods in particular, can assist in reducing risks during development in a cost-effective way. We define specific areas of risk and how they can impact product quality in a broad sense, including essential aspects such as product efficacy and patient safety. Emerging industry practices around developability are introduced, including some specific examples of applications to biotherapeutics. Furthermore, we suggest some potential workflows to illustrate how developability strategies can be introduced in practical terms during early drug development in order to mitigate risks, reduce drug attrition and ultimately increase the robustness of the biopharmaceutical supply chain. Finally, we also discuss how the implementation of such methodologies could accelerate the access of new therapeutic treatments to patients in the clinic. Hindawi Publishing Corporation 2015 2015-05-17 /pmc/articles/PMC4449898/ /pubmed/26075248 http://dx.doi.org/10.1155/2015/605427 Text en Copyright © 2015 Jesús Zurdo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Zurdo, Jesús Arnell, Andreas Obrezanova, Olga Smith, Noel Gómez de la Cuesta, Ramón Gallagher, Thomas R. A. Michael, Rebecca Stallwood, Yvette Ekblad, Caroline Abrahmsén, Lars Höidén-Guthenberg, Ingmarie Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title | Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title_full | Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title_fullStr | Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title_full_unstemmed | Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title_short | Early Implementation of QbD in Biopharmaceutical Development: A Practical Example |
title_sort | early implementation of qbd in biopharmaceutical development: a practical example |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449898/ https://www.ncbi.nlm.nih.gov/pubmed/26075248 http://dx.doi.org/10.1155/2015/605427 |
work_keys_str_mv | AT zurdojesus earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT arnellandreas earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT obrezanovaolga earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT smithnoel earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT gomezdelacuestaramon earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT gallagherthomasra earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT michaelrebecca earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT stallwoodyvette earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT ekbladcaroline earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT abrahmsenlars earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample AT hoidenguthenbergingmarie earlyimplementationofqbdinbiopharmaceuticaldevelopmentapracticalexample |